社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
CcccL
IP属地：未知
+关注
帖子 · 204
帖子 · 204
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
CcccL
CcccL
·
2021-12-17
Hello! 👋🏻
看
3,145
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-12-17
Jia lat
非常抱歉，此主贴已删除
看
4,999
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-11-30
Confusing. A lot of uncertainty
Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>
Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant A
Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>
看
5,094
回复
2
点赞
2
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-11-22
Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future
Zoom Reports Earnings Monday. Here’s What to Expect.<blockquote>Zoom 周一公布收益。以下是可以期待的。</blockquote>
Zoom Video Communications stock remains under considerable selling pressure, as investors adjust the
Zoom Reports Earnings Monday. Here’s What to Expect.<blockquote>Zoom 周一公布收益。以下是可以期待的。</blockquote>
看
3,681
回复
1
点赞
3
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-11-22
Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.
非常抱歉，此主贴已删除
看
5,054
回复
1
点赞
4
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-08-27
This is good for the consumers
非常抱歉，此主贴已删除
看
2,937
回复
评论
点赞
1
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-08-22
This is from the filing for Q2. It could have changed already because it is now Q3
非常抱歉，此主贴已删除
看
2,627
回复
1
点赞
8
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-07-28
Wow that is a lot
非常抱歉，此主贴已删除
看
4,459
回复
1
点赞
3
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-07-23
How long till singapore can open up? Retail is not doing well
非常抱歉，此主贴已删除
看
3,728
回复
1
点赞
2
编组 21备份 2
分享
举报
CcccL
CcccL
·
2021-06-26
Wow!
非常抱歉，此主贴已删除
看
4,097
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3566877420609993","uuid":"3566877420609993","gmtCreate":1603804640776,"gmtModify":1611540223391,"name":"CcccL","pinyin":"ccccl","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":93,"tweetSize":204,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":699028162,"gmtCreate":1639725624800,"gmtModify":1639725624987,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Hello! 👋🏻","listText":"Hello! 👋🏻","text":"Hello! 👋🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699028162","isVote":1,"tweetType":1,"viewCount":3145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690504803,"gmtCreate":1639676762903,"gmtModify":1639676763103,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Jia lat","listText":"Jia lat","text":"Jia lat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690504803","repostId":"2192994932","repostType":2,"isVote":1,"tweetType":1,"viewCount":4999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609688107,"gmtCreate":1638279096921,"gmtModify":1638279097066,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Confusing. A lot of uncertainty ","listText":"Confusing. A lot of uncertainty ","text":"Confusing. A lot of uncertainty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609688107","repostId":"1192203085","repostType":2,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohunote.com/m/news/1192203085?lang=zh_CN&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-30 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":5094,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872444051,"gmtCreate":1637566225446,"gmtModify":1637566889991,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future","listText":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future","text":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872444051","repostId":"1141390597","repostType":2,"repost":{"id":"1141390597","kind":"news","pubTimestamp":1637536472,"share":"https://www.laohunote.com/m/news/1141390597?lang=zh_CN&edition=full","pubTime":"2021-11-22 07:14","market":"us","language":"en","title":"Zoom Reports Earnings Monday. Here’s What to Expect.<blockquote>Zoom 周一公布收益。以下是可以期待的。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141390597","media":"Barrons","summary":"Zoom Video Communications stock remains under considerable selling pressure, as investors adjust the","content":"<p>Zoom Video Communications stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world emerges from the pandemic.</p><p><blockquote>随着Zoom Video通信公司的增长率持续下降以及世界走出疫情，投资者调整了对这家视频会议公司的看法，该公司的股票仍然面临相当大的抛售压力。</blockquote></p><p> Zoom (ticker: ZM) reports financial results after the close of trading on Monday. For the fiscal third quarter through Oct. 31, the company has projected revenue of $1.02 billion, with non-GAAP earnings of $1.07 to $1.08 a share. Street estimates call for $1.02 billion and $1.09 a share.</p><p><blockquote>Zoom（股票代码：ZM）周一收盘后公布财务业绩。截至 10 月 31 日的第三财季，该公司预计收入为 10.2 亿美元，非 GAAP 每股收益为 1.07 美元至 1.08 美元。华尔街预计看涨期权股价为 10.2 亿美元，每股 1.09 美元。</blockquote></p><p> Zoom shares have fallen 28% since the company reported results for the July quarter, reflecting growing concerns about both slowing growth and increased competition from other players in the videoconferencing space, in particular Microsoft Teams. Since Zoom last reported financial results, the company suffered the collapse of its proposed acquisition of the call-center software operator Five9 (FIVN).</p><p><blockquote>自该公司公布 7 月份季度业绩以来，Zoom 股价已下跌 28%，反映出人们越来越担心增长放缓以及来自视频会议领域其他参与者（尤其是微软团队）的竞争加剧。自 Zoom 上次公布财务业绩以来，该公司收购看涨期权中心软件运营商 Five9 (FIVN) 的提议失败了。</blockquote></p><p> With its core videoconferencing business under pressure, Zoom has been pushing more aggressively into new areas, in particular Zoom Phone, the company’s cloud-based telephony business. But competition in that market remains fierce, from RingCentral and others. At the same time, there are concerns that usage of the core Zoom service is falling as schools and businesses reopen, reducing the need to be in Zoom meetings throughout the day.</p><p><blockquote>由于核心视频会议业务面临压力，Zoom 一直在更积极地进军新领域，尤其是公司基于云的电话业务 Zoom Phone。但来自 RingCentral 和其他公司的市场竞争仍然激烈。与此同时，有人担心随着学校和企业重新开放，核心 Zoom 服务的使用量正在下降，从而减少了全天参加 Zoom 会议的需求。</blockquote></p><p> Citi analyst Tyler Radke wrote in a research note last week that the setup for Zoom’s earnings looks mixed. “Potential headwinds from reopening churn and summer seasonality” are likely to limit revenue upside, he said.</p><p><blockquote>花旗分析师泰勒-拉德克（Tyler Radke）上周在一份研究报告中写道，Zoom 的盈利情况看起来好坏参半。他说，“重新开放的客户流失和夏季季节性带来的潜在阻力 ”可能会限制收入的上升空间。</blockquote></p><p> However, Radke also notes that “sentiment is quite negative,” and that guidance was relatively conservative—he sees potential for a 2% to 3% beat on the revenue line. That said, Radke also says Zoom is unlikely to aggressively raise full-year guidance “given few signs of incremental improvement” in the business.</p><p><blockquote>不过，拉德克也指出，“市场情绪相当消极”，而且指引也相对保守--他认为收入有可能增长 2% 到 3%。尽管如此，拉德克还表示，“鉴于业务几乎没有逐步改善的迹象”，Zoom 不太可能大幅提高全年指引。</blockquote></p><p> Radke maintains his Neutral rating and $304 target on the stock, anticipating that the company’s growth rate is headed to below 20% in fiscal 2023 and beyond. And he sees the opportunities in Phone and other areas as small, and “likely unable to offset a larger-scale deceleration” in the core video meetings segment.</p><p><blockquote>拉德克维持对该股的中性评级和 304 美元的目标价，预计该公司在 2023 财年及以后的增长率将低于 20%。他认为电话和其他领域的机会很小，而且 “可能无法抵消核心视频会议领域更大规模的减速”。</blockquote></p><p> Morgan Stanley analyst Meta Marshall is more upbeat. She maintains an Overweight rating on the stock, though she trimmed her target price this week to $365, from $400. She thinks the Street has overly discounted Zoom’s enterprise business, and says the company remains in the early days of a $70 billion opportunity in unified communications. Any signs of weakness in the small- and medium-size business market could pressure the stock, she warns, but adds that she would be a buyer on any weakness connected with earnings.</p><p><blockquote>摩根士丹利分析师梅塔·马歇尔则更加乐观。她维持该股的跑赢大盘评级，尽管她本周将目标价从 400 美元下调至 365 美元。她认为华尔街过度低估了 Zoom 的企业业务，并表示该公司在统一通信领域仍处于 700 亿美元机会的早期阶段。她警告说，中小企业市场疲软的任何迹象都可能给该股带来压力，但她补充说，她将买入与盈利相关的任何疲软。</blockquote></p><p> For the fiscal fourth quarter ending in January, the Street consensus calls for revenue of $1.02 billion and profits of $1.09 a share. Zoom last quarter projected fiscal 2022 full-year revenue of $4.01 billion to $4.02 billion, with earnings of $4.75 to $4.79 a share.</p><p><blockquote>截至 1 月份的第四财季，华尔街一致评级收入为 10.2 亿美元，每股利润为 1.09 美元。Zoom上季度预计2022财年全年收入为40.1亿至40.2亿美元，每股收益为4.75美元至4.79美元。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Reports Earnings Monday. Here’s What to Expect.<blockquote>Zoom 周一公布收益。以下是可以期待的。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Reports Earnings Monday. Here’s What to Expect.<blockquote>Zoom 周一公布收益。以下是可以期待的。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-22 07:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Zoom Video Communications stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world emerges from the pandemic.</p><p><blockquote>随着Zoom Video通信公司的增长率持续下降以及世界走出疫情，投资者调整了对这家视频会议公司的看法，该公司的股票仍然面临相当大的抛售压力。</blockquote></p><p> Zoom (ticker: ZM) reports financial results after the close of trading on Monday. For the fiscal third quarter through Oct. 31, the company has projected revenue of $1.02 billion, with non-GAAP earnings of $1.07 to $1.08 a share. Street estimates call for $1.02 billion and $1.09 a share.</p><p><blockquote>Zoom（股票代码：ZM）周一收盘后公布财务业绩。截至 10 月 31 日的第三财季，该公司预计收入为 10.2 亿美元，非 GAAP 每股收益为 1.07 美元至 1.08 美元。华尔街预计看涨期权股价为 10.2 亿美元，每股 1.09 美元。</blockquote></p><p> Zoom shares have fallen 28% since the company reported results for the July quarter, reflecting growing concerns about both slowing growth and increased competition from other players in the videoconferencing space, in particular Microsoft Teams. Since Zoom last reported financial results, the company suffered the collapse of its proposed acquisition of the call-center software operator Five9 (FIVN).</p><p><blockquote>自该公司公布 7 月份季度业绩以来，Zoom 股价已下跌 28%，反映出人们越来越担心增长放缓以及来自视频会议领域其他参与者（尤其是微软团队）的竞争加剧。自 Zoom 上次公布财务业绩以来，该公司收购看涨期权中心软件运营商 Five9 (FIVN) 的提议失败了。</blockquote></p><p> With its core videoconferencing business under pressure, Zoom has been pushing more aggressively into new areas, in particular Zoom Phone, the company’s cloud-based telephony business. But competition in that market remains fierce, from RingCentral and others. At the same time, there are concerns that usage of the core Zoom service is falling as schools and businesses reopen, reducing the need to be in Zoom meetings throughout the day.</p><p><blockquote>由于核心视频会议业务面临压力，Zoom 一直在更积极地进军新领域，尤其是公司基于云的电话业务 Zoom Phone。但来自 RingCentral 和其他公司的市场竞争仍然激烈。与此同时，有人担心随着学校和企业重新开放，核心 Zoom 服务的使用量正在下降，从而减少了全天参加 Zoom 会议的需求。</blockquote></p><p> Citi analyst Tyler Radke wrote in a research note last week that the setup for Zoom’s earnings looks mixed. “Potential headwinds from reopening churn and summer seasonality” are likely to limit revenue upside, he said.</p><p><blockquote>花旗分析师泰勒-拉德克（Tyler Radke）上周在一份研究报告中写道，Zoom 的盈利情况看起来好坏参半。他说，“重新开放的客户流失和夏季季节性带来的潜在阻力 ”可能会限制收入的上升空间。</blockquote></p><p> However, Radke also notes that “sentiment is quite negative,” and that guidance was relatively conservative—he sees potential for a 2% to 3% beat on the revenue line. That said, Radke also says Zoom is unlikely to aggressively raise full-year guidance “given few signs of incremental improvement” in the business.</p><p><blockquote>不过，拉德克也指出，“市场情绪相当消极”，而且指引也相对保守--他认为收入有可能增长 2% 到 3%。尽管如此，拉德克还表示，“鉴于业务几乎没有逐步改善的迹象”，Zoom 不太可能大幅提高全年指引。</blockquote></p><p> Radke maintains his Neutral rating and $304 target on the stock, anticipating that the company’s growth rate is headed to below 20% in fiscal 2023 and beyond. And he sees the opportunities in Phone and other areas as small, and “likely unable to offset a larger-scale deceleration” in the core video meetings segment.</p><p><blockquote>拉德克维持对该股的中性评级和 304 美元的目标价，预计该公司在 2023 财年及以后的增长率将低于 20%。他认为电话和其他领域的机会很小，而且 “可能无法抵消核心视频会议领域更大规模的减速”。</blockquote></p><p> Morgan Stanley analyst Meta Marshall is more upbeat. She maintains an Overweight rating on the stock, though she trimmed her target price this week to $365, from $400. She thinks the Street has overly discounted Zoom’s enterprise business, and says the company remains in the early days of a $70 billion opportunity in unified communications. Any signs of weakness in the small- and medium-size business market could pressure the stock, she warns, but adds that she would be a buyer on any weakness connected with earnings.</p><p><blockquote>摩根士丹利分析师梅塔·马歇尔则更加乐观。她维持该股的跑赢大盘评级，尽管她本周将目标价从 400 美元下调至 365 美元。她认为华尔街过度低估了 Zoom 的企业业务，并表示该公司在统一通信领域仍处于 700 亿美元机会的早期阶段。她警告说，中小企业市场疲软的任何迹象都可能给该股带来压力，但她补充说，她将买入与盈利相关的任何疲软。</blockquote></p><p> For the fiscal fourth quarter ending in January, the Street consensus calls for revenue of $1.02 billion and profits of $1.09 a share. Zoom last quarter projected fiscal 2022 full-year revenue of $4.01 billion to $4.02 billion, with earnings of $4.75 to $4.79 a share.</p><p><blockquote>截至 1 月份的第四财季，华尔街一致评级收入为 10.2 亿美元，每股利润为 1.09 美元。Zoom上季度预计2022财年全年收入为40.1亿至40.2亿美元，每股收益为4.75美元至4.79美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/zoom-stock-earnings-preview-51637356886?mod=hp_LEADSUPP_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.barrons.com/articles/zoom-stock-earnings-preview-51637356886?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141390597","content_text":"Zoom Video Communications stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world emerges from the pandemic.\nZoom (ticker: ZM) reports financial results after the close of trading on Monday. For the fiscal third quarter through Oct. 31, the company has projected revenue of $1.02 billion, with non-GAAP earnings of $1.07 to $1.08 a share. Street estimates call for $1.02 billion and $1.09 a share.\nZoom shares have fallen 28% since the company reported results for the July quarter, reflecting growing concerns about both slowing growth and increased competition from other players in the videoconferencing space, in particular Microsoft Teams. Since Zoom last reported financial results, the company suffered the collapse of its proposed acquisition of the call-center software operator Five9 (FIVN).\nWith its core videoconferencing business under pressure, Zoom has been pushing more aggressively into new areas, in particular Zoom Phone, the company’s cloud-based telephony business. But competition in that market remains fierce, from RingCentral and others. At the same time, there are concerns that usage of the core Zoom service is falling as schools and businesses reopen, reducing the need to be in Zoom meetings throughout the day.\nCiti analyst Tyler Radke wrote in a research note last week that the setup for Zoom’s earnings looks mixed. “Potential headwinds from reopening churn and summer seasonality” are likely to limit revenue upside, he said.\nHowever, Radke also notes that “sentiment is quite negative,” and that guidance was relatively conservative—he sees potential for a 2% to 3% beat on the revenue line. That said, Radke also says Zoom is unlikely to aggressively raise full-year guidance “given few signs of incremental improvement” in the business.\nRadke maintains his Neutral rating and $304 target on the stock, anticipating that the company’s growth rate is headed to below 20% in fiscal 2023 and beyond. And he sees the opportunities in Phone and other areas as small, and “likely unable to offset a larger-scale deceleration” in the core video meetings segment.\nMorgan Stanley analyst Meta Marshall is more upbeat. She maintains an Overweight rating on the stock, though she trimmed her target price this week to $365, from $400. She thinks the Street has overly discounted Zoom’s enterprise business, and says the company remains in the early days of a $70 billion opportunity in unified communications. Any signs of weakness in the small- and medium-size business market could pressure the stock, she warns, but adds that she would be a buyer on any weakness connected with earnings.\nFor the fiscal fourth quarter ending in January, the Street consensus calls for revenue of $1.02 billion and profits of $1.09 a share. Zoom last quarter projected fiscal 2022 full-year revenue of $4.01 billion to $4.02 billion, with earnings of $4.75 to $4.79 a share.","news_type":1,"symbols_score_info":{"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":3681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872446427,"gmtCreate":1637566000969,"gmtModify":1637566001105,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.","listText":"Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.","text":"Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872446427","repostId":"1159391988","repostType":4,"isVote":1,"tweetType":1,"viewCount":5054,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":819858039,"gmtCreate":1630057303421,"gmtModify":1704955294406,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"This is good for the consumers ","listText":"This is good for the consumers ","text":"This is good for the consumers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819858039","repostId":"2162301220","repostType":2,"isVote":1,"tweetType":1,"viewCount":2937,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832292155,"gmtCreate":1629634342577,"gmtModify":1631890014949,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"This is from the filing for Q2. It could have changed already because it is now Q3","listText":"This is from the filing for Q2. It could have changed already because it is now Q3","text":"This is from the filing for Q2. It could have changed already because it is now Q3","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/832292155","repostId":"1133515985","repostType":4,"isVote":1,"tweetType":1,"viewCount":2627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801034666,"gmtCreate":1627471895155,"gmtModify":1631890014949,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Wow that is a lot","listText":"Wow that is a lot","text":"Wow that is a lot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/801034666","repostId":"2154386941","repostType":2,"isVote":1,"tweetType":1,"viewCount":4459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175678219,"gmtCreate":1627031088631,"gmtModify":1631890014951,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"How long till singapore can open up? Retail is not doing well","listText":"How long till singapore can open up? Retail is not doing well","text":"How long till singapore can open up? Retail is not doing well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175678219","repostId":"1133956405","repostType":4,"isVote":1,"tweetType":1,"viewCount":3728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125331641,"gmtCreate":1624649879683,"gmtModify":1631890014957,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"title":"","htmlText":"Wow!","listText":"Wow!","text":"Wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125331641","repostId":"2146076005","repostType":2,"isVote":1,"tweetType":1,"viewCount":4097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}